CCL2 and melanoma: BRIRi can generate anti‐melanoma immunomodulatory functions by upregulating CD8+ T‐cell‐recruiting CCL3 and CCL4 expressed by melanoma cells32 and by downregulating the expression of the immunosuppressive chemokine CCL2.33